Carvolix (CVX.PA) Stock Price

Carvolix Price

Euronext·CLOSED
5.38
​
Market closed

Over the last 8 years Carvolix grew revenue by 146.7% annually, reaching 4.12 M EUR. For Carvolix, the net margin of -357.9% is up versus -1,737.7% a few years ago. The consensus 12-month price target for Carvolix is 3.88 EUR, about 28.0% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Carvolix stock price

Access this data via the Eulerpool API

Carvolix business model & stock analysis

Affluent Medical SA provides treatments for serious and widespread diseases. The company is headquartered in Aix-En-Provence, Paca and currently employs 54 full-time employees. The company went IPO on 2021-06-14. The company designs minimally invasive prostheses at mimicking human anatomy and restoring native physiology for critical functions in cardiovascular and urological therapies. The company provides several products such as Kalios, Epygon, Artus. The company helps in treating heart disease and urinary incontinence. The firm provides transcatheter and flow control technologies, such as mimicry of anatomy and restoration of physiology minimally invasive implant procedures, optimized and biocompatible components.

Frequently asked questions about Carvolix

Analysts currently set an average price target of 3.91 EUR for the Carvolix stock (median: 3.88 EUR), implying -27.3 % versus the latest price. The consensus is based on 7 analyst ratings.

8 analysts currently rate the Carvolix stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Carvolix to generate revenue of 1.89 M EUR and earnings per share of -0.68 EUR.

The Carvolix share (CVX.PA) is listed on 4 stock exchanges, including: Frankfurt (0JZ.F), München (0JZ.MU), Paris (AFME.PA).

The expected revenue of Carvolix is 1.89 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Carvolix is -26.62 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Carvolix is currently -7.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Carvolix stock.

The price-to-sales ratio (P/S) of Carvolix is currently 112.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Carvolix stock.

The Eulerpool Quality Score for Carvolix is 2/10.

The ISIN of Carvolix is FR0013333077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Carvolix is A3CRZT. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Carvolix is CVX.PA. The ticker symbol is used to trade Carvolix shares on the stock exchange.

Fair ValueTerminal
5.43 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
EUR
Initial public offering
Jun 14, 2021
ISIN
FR0013333077
Cusip
F0094F107
Market capitalization
318.71 M EURSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-7.95
P/Ee 2027
-7.77
P/Ee 2028
-12.13
P/Ee 2029
34.99
P/Se
112.08
EV/EBIT
—
P/B Ratio
57.42
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-84.38 %
Last updated Oct 12, 2026, 4:47 AM

Carvolix Peer Group

Carvolix Ticker

EURONEXT · AFME.PAFRANKFURT · 0JZ.FMUNICH · 0JZ.MUPARIS · AFME.PA

Carvolix FIGI

AFME:FP · BBG00L2LLFD3AFMEEUR:XS · BBG00L4C1607AFMEEUR:XH · BBG00L4C1661AFMEEUR:XF · BBG00L4C16B5AFMEEUR:XE · BBG00L4C16G0AFMEEUR:XJ · BBG00L4C16J7AFMEEUR:XL · BBG00L4C16L4AFMEEUR:XG · BBG00L4C16N2AFMEEUR:XO · BBG00L4C16Q9AFMEEUR:XA · BBG00L4C16X1ALAMEUR:E1 · BBG00L4C16Y0AFMEEUR:XT · BBG00L4C1705

All fundamentals and in-depth analysis of Carvolix

Our stock analysis for Carvolix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Carvolix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.